Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-08-15
2006-08-15
Richter, Johann (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233500, C514S233800, C514S252010, C514S254040, C514S318000, C514S444000, C548S242000, C546S207000, C546S272100, C544S368000, C544S357000, C540S480000, C540S593000, C540S602000
Reexamination Certificate
active
07091199
ABSTRACT:
The compounds are of the class of thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives, useful as D4antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.
REFERENCES:
patent: 4075227 (1978-02-01), Jones et al.
patent: 4085114 (1978-04-01), Adachi et al.
patent: 4355037 (1982-10-01), Strupczewski et al.
patent: 4408053 (1983-10-01), Strupczewski et al.
patent: 4408054 (1983-10-01), Strupczewski et al.
patent: 4427691 (1984-01-01), Shutske et al.
patent: 4452804 (1984-06-01), Shutske et al.
patent: 4469869 (1984-09-01), Strupczewski et al.
patent: 4504669 (1985-03-01), Shutske et al.
patent: 4528376 (1985-07-01), Strupczewski et al.
patent: 4644064 (1987-02-01), Shutske et al.
patent: 4728651 (1988-03-01), Ong et al.
patent: 4769472 (1988-09-01), Ong et al.
patent: 5114936 (1992-05-01), Wettlaufer et al.
patent: 5143923 (1992-09-01), Hrib et al.
patent: 5177088 (1993-01-01), Effland et al.
patent: 5180834 (1993-01-01), Wettlaufer et al.
patent: 5225412 (1993-07-01), Hrib et al.
patent: 5225414 (1993-07-01), Henning et al.
patent: 5254595 (1993-10-01), Guzzi et al.
patent: 5256672 (1993-10-01), Wettlaufer et al.
patent: 5321037 (1994-06-01), Nagano et al.
patent: 5328920 (1994-07-01), Effland et al.
patent: 5340833 (1994-08-01), Bridges et al.
patent: 5576319 (1996-11-01), Baker et al.
patent: 5593994 (1997-01-01), Batt et al.
patent: 5696113 (1997-12-01), Palermo et al.
patent: 5780474 (1998-07-01), Peglion et al.
patent: 5843940 (1998-12-01), Cullinan et al.
patent: 5852022 (1998-12-01), Palermo et al.
patent: 5856503 (1999-01-01), Aebi et al.
patent: 5932586 (1999-08-01), Batt et al.
patent: 5965554 (1999-10-01), Palermo et al.
patent: 6008348 (1999-12-01), Palermo et al.
patent: 6022880 (2000-02-01), Effland et al.
patent: 6103724 (2000-08-01), Laszlovszky et al.
patent: 6121293 (2000-09-01), Cullinan et al.
patent: 0058977 (1982-09-01), None
patent: 0221414 (1987-05-01), None
patent: 0729955 (1996-09-01), None
patent: 1269776 (1972-04-01), None
patent: 10095770 (1998-04-01), None
patent: WO 92/08718 (1992-05-01), None
patent: WO 97/23482 (1997-07-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/40027 (1997-10-01), None
patent: WO 99/40067 (1999-08-01), None
patent: WO 01/19833 (2001-03-01), None
patent: WO 2001019833 (2001-03-01), None
Van Tol et al., “Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”, Letters to Nature, vol. 350 (1991) pp. 610-614.
Newman, “Novel pharmacotherapies for Cocaine abuse 1997-2000”, Medicinal Chemistry Section, National Institute on Drug Abuse-Intramural Research Program, Expect Opinion on Therapeutic Patients, (2000), 10 (7).
Asghari, V., et. al., Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes, Molecular Pharmacology vol. 46, pp. 364-373 (1994).
Bassitt, D.P., et. al., Clozapine Efficacy in Tardive Dyskinesia in Schizoprenic Patients, European Archives of Psychiatry and Clinical Neuroscience vol. 248, pp. 209-211 (1998).
Benjamin, J., et. al., Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking, Nature Genetics vol. 12, pp. 81-84 (1996).
Bryce, M., et. al., Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrroles: Precursors for the Prepration of Conducting Polymers, Synthetic Metal, vol. 26, (1988) pp. 153-168.
Corbett, R., et. al., Iloperidone: Preclinical Profile and Early Clinical Evaluation, CNS Drug Review vol. 3, No. 2, pp. 120-147 (1997).
Crenshaw, R.R., et. al., Potential Antifertility Agents, 1. Substituted Diarl Derivatives of Benzo[b]Thiophenes, Benzo[b]furans, 1H-2-Benzothiapyrans, and 2H-1-Benzothiapyrans1, Journal of Medicinal Chemistry, vol. 14, No. 12, (1971) pp. 1185-1190.
Cruz, C., et. al., Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics, Neuroscience Letters vol. 231, pp. 1-4, (1997).
Ebstein, R.E., et. al., Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking, Nature Genetics vol. 12, (1996) pp. 78-80.
Elworthy, T.R., et. al., N-Arylpiperazinyl-N-Propytamino Derivatives of Heteroaryl Amides as Functional Uroselective a1-Adrenoceptor Antagonists, Indian Journal of Chemistry—part B Organic Including Medicinal vol. 40, pp. 2674-1348, (1985).
Erenberg, G., et. al., Giles De La Tourette's Syndrome: Effects of Stimulant Drugs, Neurology vol. 35, No. 35, pp. 1346-1348, (1985).
Factor, S.A., et. al., The Emerging Role od Clozapine in the Treatment od Movement Disorders, Movement Disorders vol. 12, No. 4 (1997) pp. 483-496.
Feldpausch, D.L., et. al., The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics vol. 266, pp. 497-508 (1998).
Friedman, J.H., et. al., Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Result of an Open Label for Pilot Study, Clinical Neuropharmacology, vol. 21, No. 5 pp. 285-288 (1998).
Grice, D.E., et. al., Linkage Disequilibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission-Disequilibrium Test, American Journal of Human Genetics vol. 59, pp. 644-652 (1996).
Helsley, G.C., et. al., Piperidyalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxypiperidyl)ethyl]Indoles, Journal of Medicinal Chemistry, (1978), vol. 21, No. 3 pp. 309-312.
Lahoste, G., et. al., Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry vol. 1, pp. 121-124 (1996).
Lahti, R.A., et. al., Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A [3H]NGD-94-1 Study, Molecular Psychiatry vol. 3, pp. 528-533 (1998).
Magdo, I., et. al., 3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity, Database Chemabs 'Online! Chemical Abstracts Service, Columbus, Ohio, US.
Ricketts, H., et. al., Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat Polymorphism with Parkinson's Disease, Clinical Genetics vol. 54, pp. 33-38 (1998).
Rubinstein, M., et. al., Mice Lacking Dopamine D4 Receptors are Supersitive to Ethanol, Cocaine, and Methamphetamine, Cell, vol. 991-1001 (1997).
Sall, D., e.t al., Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure—Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry vol. 40, No. 22, (1997) pp. 3489-3493.
Schoder, J., et. al., D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 123I-Iodobenzamide Single Photon Emission Compouted Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry vol. 43, pp. 660-665, (1998).
Seeman, P., et. al., Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selectivefor D4 Receptors, Neuropoychoppharmacology vol. 16, Iss. 2, pp. 92-135 (1997).
Seeman, P., et. al., Schizophrenia: Eleveation of dopamine D4-like sites, using [3H]Nemonapride and [125I]Epidepride , European Journal of Pharmacology vol. 286 (1995) R3-R5.
Shields, P.G., et. al., Dopamine D4 Receptors
Ayers Timothy A.
Jurcak John G.
Lee George E.
Aventis Pharmaceuticals Inc.
Kurys Barbara E.
Richter Johann
Sackey Ebenezer
LandOfFree
Thienoisoxazole phenoxy unsubstituted ethyl and propyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienoisoxazole phenoxy unsubstituted ethyl and propyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienoisoxazole phenoxy unsubstituted ethyl and propyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3712536